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ABSTRACT This paper explores commonalities in the experience and unmet needs of idiopathic
pulmonary fibrosis (IPF) patients and carers in Europe throughout the care pathway, focusing specifically
on the unmet communication needs of patients and carers.
Four patient organisations/groups in Europe held focus groups (Italy (seven patients and four carers);
Belgium (six patients); Ireland (23 patients and 10 carers); and England, UK (five patients and three
carers)). A focus group schedule was provided and translated into the language of each focus group by the
European Lung Foundation (ELF). Content analysis was conducted by the ELF and verified by the authors
of the paper.
Three main themes emerged: professional−patient, professional−professional and patient−patient
communication. Within these themes, eight priority areas were highlighted by two or more of the focus
groups. In addition, 17 suggested action points were identified.
Patients and carers in Europe have unmet communication needs, which could be met by specialist
physicians and specialist centres providing more effective information and signposting to support services,
including support groups and patient organisations.
@ERSpublications
People with IPF and their carers reported communication challenges with healthcare
professionals, between healthcare professionals and from patient to patient, during four focus
groups held in different countries in Europe http://bit.ly/2LaJXQF
Cite this article as: Masefield S, Cassidy N, Ross D, et al. Communication difficulties reported by
patients diagnosed with idiopathic pulmonary fibrosis and their carers: a European focus group
study. ERJ Open Res 2019; 5: 00055-2019 [https://doi.org/10.1183/23120541.00055-2019].
Copyright ©ERS 2019. This article is open access and distributed under the terms of the Creative Commons Attribution
Non-Commercial Licence 4.0.
Received: Feb 27 2019 | Accepted after revision: April 09 2019
https://doi.org/10.1183/23120541.00055-2019 ERJ Open Res 2019; 5: 00055-2019
ORIGINAL ARTICLE
INTERSTITIAL LUNG DISEASE
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and debilitating interstitial lung disease (ILD),
with a median untreated survival of 2−5 years from diagnosis. The major impact of IPF on quality of life
for patients and families is increasingly recognised, with the need for high-quality information, support
and appropriate therapies [1, 2].
Patient-centred care, with informed patients as active partners in their treatment, is grounded on effective
communication between the patient, their physician, and other healthcare professionals and support
services [3, 4]. Clear, effective and positive communication between the physician and the patient
improves outcomes in patient satisfaction, engagement, compliance and self-management [4]. Few studies
in IPF have focused on communication between patients and healthcare professionals across the care
pathway (from receiving a diagnosis to discussions of end-of-life care) and its impact on the patient
experience [5, 6]. The goals of this qualitative study were to identify the communication challenges
reported by patients and carers across Europe, and elicit ideas for improvement.
Methods
In 2013, the European Lung Foundation (ELF) (www.europeanlung.org) established a working group on
patient-centred issues for people with IPF comprised of six healthcare professionals from the European
Respiratory Society, an IPF patient, a family carer who also represented the Irish Lung Fibrosis Association
(ILFA) and an ELF coordinator. The working group identified seven topics for patient and carer
consultation, which are listed in the first column of table 1.
Focus group discussions were considered the optimal way to obtain direct input from a variety of patients
and carers on their real-life experiences of these topics. Using a focus group approach was also the most
efficient way to elicit input from patients and carers in different European countries. ELF invited eight
European patient organisations to hold focus groups to discuss the topics proposed by the working group
with their patient and carer members. Four organisations participated: AMA Fuori dal buio, Italy;
Belgische Vereniging voor Longfibrose (BVL), Belgium; ILFA; and the Bristol Pulmonary Fibrosis Support
Group, England, UK.
All focus group participants were provided with information in advance and gave informed consent to
participate. An ILD nurse was present at each focus group, except those in Ireland. A psychologist was also
present at the group in England. ELF produced a systematic guide for focus group leaders and note-takers
to ensure that each group covered the topics in a structured way, using the same schedule and timings.
The guide was produced in English and professionally translated into the other languages of the
participating organisations.
The note-taker in each focus group recorded the discussion and produced a report, which was translated
into English where necessary. Report-writing guidance was provided to enable comparison between
reports. The reports indicated the points on which participants reached consensus and also those points in
which there were differences of opinion or experience (e.g. “all participants agreed”, “the majority of
participants agreed” or “two or more people’s opinions differed”). The reports were analysed individually
and collectively, using content analysis. Analysis of emergent themes highlighted key patient priorities for
patients and carers in different countries. The analysis was reviewed and independently verified by
S. Masefield, N. Cassidy and A. Wells. Themes raised by fewer than two groups were discounted. Different
numbers of patients and carers participated in the different focus groups, but the content analysis gave
equal weighting to contributions made by each group.
TABLE 1 Topics identified for patient and carer consultation
By the working group By the focus groups
Definitions of mild, moderate and severe IPF
Communication of diagnosis
Misdiagnosis and incorrect treatment
Medication issues
Patient-centred outcomes
Ongoing care and advanced care
New research on diagnosis and treatment
Lung transplantation
Financial impact of IPF
Reliable information and doctor–patient communication
Maximising quality of life
Patient and family support
Exercise and pulmonary rehabilitation
IPF: idiopathic pulmonary fibrosis.
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A further six items were identified by the focus groups and are listed in the second column of table 1.
Results
Four national patient organisations held a total of eight focus groups between July 2013 and March 2015,
and submitted a report to ELF. 58 people participated in the focus groups across Europe: five patients and
three carers in England; seven patients and four carers in Italy (two focus groups); six patients in Belgium;
and 23 patients and 10 carers in Ireland (five focus groups).
The communication issues highlighted by the focus group participants were categorised into three main
themes with several priority areas (table 2).
The patients’ and carers’ experiences are summarised and, where appropriate, described in their own
words. Suggestions for ways to improve communication, build better relationships and enhance the
healthcare experience are also presented.
Professional−patient
Effective and empathic communication
For effective communication with their physicians, patients and carers wanted plain language, honesty and
empathy. They identified the importance of having adequate time available to ask their doctors questions,
especially at the point of diagnosis: “Doctors should be sensitive when delivering a diagnosis and
prognosis to patients. The delivery of a diagnosis should not be rushed as the news is life changing. Time
should not be an issue.” Ideally, patients would like a follow-up appointment 1−4 weeks after the
diagnosis, giving them time to overcome the shock of the diagnosis so that at the follow-up appointment
they are able to concentrate on their medical information needs relating to treatment and management.
Patients wanted information about their diagnosis and test results directly from an ILD specialist who
could explain what the diagnosis meant in terms they could understand. Many patients did not
comprehend the terminology of the staging of their lung disease, and how descriptions of “mild”,
“moderate” or “severe” related to their current health status, predicted life span and quality of life: “If
somebody says to you it’s mild, moderate or severe, all that immediately goes through your mind is does
that mean I have a short life or a long one? It doesn’t tell you what you’re faced with.” Patients placed
value on knowing their spirometry and 6-min walk test results, and comparing these with previous results,
but wanted to know how this related to their condition in terms of their ability to perform daily activities,
levels of fatigue and breathlessness.
Patients valued a balance of honesty and hope. They wanted the physicians to be realistic about the
diagnosis and communicate the uncertainties of the progression of IPF, but without being too negative:
“The diagnosis was communicated to me in a realistic manner. ‘There is no treatment and no cure but’ –
I remember the doctor emphasised that but – ‘but there is a medicine that gives encouraging results’.”
They also felt that the clinician should recognise the patient’s fears.
Patients stated that the key messages to communicate at the point of diagnosis are: 1) what IPF is, 2) that
there is no cure, and 3) that IPF is chronic and progressive, but 4) that there are effective treatments to
slow progression and manage symptoms.
The patients wanted to be able to access as much or as little information as they needed and the view did
vary across the focus groups, with some patients wanting to know all they could about their condition
(including how it developed, why it might have developed, the stages of it, prognosis, therapy options,
etc.), whilst other patients just want to know that they have it. This led to the patients’ perspective that
layered information sources are needed so that those that want the basics can find them easily and those
that want more can drill down to find it when they want to. It is important to note that these information
TABLE 2 Main themes and priority areas highlighted by the idiopathic pulmonary fibrosis focus
group participants
Professional−patient Professional−professional Patient−patient
Effective and empathic
communication
Point of contact
Medication guidance
Advanced care planning
Specialist physician to other healthcare
professionals
Referral to rehabilitation and support
services
Support groups and patient
organisations
Carer and family support
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needs may change as patients come to terms with the diagnosis and their condition advances. Many focus
group participants considered the specialist physician and centre their primary source of information. The
patients often wanted their partner/family involved in the treatment decision-making, but noted that the
carer’s information needs may vary from the patient’s and should be managed sensitively by the physician.
The focus group participants wanted to know and understand the treatment options to enable them to
make informed decisions. Some patients wanted to understand why certain options were not available to
them (e.g. lung transplantation). Understanding the options could help patients come to terms with their
diagnosis and provide hope: “Being told you have this and there is nothing you can do is frightening. I
was told that I wasn’t suitable for transplant so I felt in a position of no hope. I just had to sit down and
take what was coming with no hope, and that was the worst of all.”
The focus group members also wondered if guidance could help patients and carers to communicate more
effectively with their physicians. The patients suggested that if they knew the information and detail that
was required for their review appointments, they could keep a health diary and report changes that could
be important indicators of disease progression or non-IPF pathology. The patients questioned if being
more communicative about their health status could have accelerated their diagnosis. For example, one
patient felt that they should have “taken a more proactive approach and taken personal responsibility for
getting a diagnosis”.
Point of contact
Each focus group stated the importance of having a point of contact or “helpline” that they could contact
by telephone, e-mail or in person outside of their scheduled clinical appointments; for example, a
healthcare professional with specialist knowledge of IPF, such as an ILD nurse. The ILD nurse could also
meet the patient’s need to see a specialist 1–4 weeks after their initial diagnosis: “I know I can always
phone my ILD Nurse Specialist and talk to her. She is a fountain of knowledge about it all. When I come
for my appointment, she always spends time going through everything; that’s really vital.” The patients
found it reassuring to have a nurse who they could contact if they thought their symptoms had changed,
and could spend time explaining their results and listening to their concerns.
This point of contact could also meet the patients’ ongoing information needs by providing clear and
concise printed information and alerting them to plain language resources online. Each focus group raised
concerns about the quality and reliability of information via the Internet, which could sometimes be
alarming to read. They suggested that specialist centres provide a list of sites that provide accurate and
reliable information, and warn the patient about websites that provide incorrect information. The point of
contact should also be able to facilitate practical support (e.g. disability and welfare benefits, and ongoing
research studies) if they are interested.
Medication guidance
Many patients felt they took too many tablets, and sought explanations and reassurances from their
physician, as well as information on the medication’s side-effects and strategies to manage them. They
wanted someone they could go to when they have concerns about drug interactions: “I am certain there is
an interaction going on between some of the tablets but I don’t know who to talk to. You feel like you
have no-one in control of it.” The patients reported reading the drug information leaflets but finding them
frightening or inaccessible due to the medical language.
Medications prescribed by different specialists for comorbidities also caused anxiety. The patients wanted
reassurance that different specialists were communicating with each other in order to reach agreement on
drug regimens. The patients lacked confidence in local nonspecialised doctors, who they felt had
inadequate knowledge of IPF. This is being and can be improved further with the shared-care model,
where local physicians can specialise in conditions such as ILD.
Advanced care planning
There was some discomfort within the focus groups with discussions about advanced care planning/
end-of-life care because some individuals preferred to focus on the present and not the future. Some
individuals had attempted to raise the subject with their partner or families but were prevented: “I have
tried to talk about this with my wife, but she interrupted me suddenly; she does not even want to hear me
talk.”
A number of patients found it hard to consider advanced care planning until it became a necessity.
However, they did agree that it would be important to have prompt access to a team who would be able to
support them in the community as their condition changes and they become less well. Although some of
the focus group patients were uncomfortable discussing the topic in a peer group setting, they felt there
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was a need for their doctor to speak with them one-to-one, sensitively, to engage in the discussion when
they raised it or when the physician identified a medical imperative.
Professional−professional
ILD physician to other healthcare professionals
People with IPF are often reviewed by several doctors, including their specialist ILD physician, other
doctors within the ILD centre, respiratory and/or nonrespiratory specialists for comorbidities, and their
local doctor. Patients raised concerns that poor interprofessional communication could negatively impact
their health; for example, patients questioned the quality of the care they received when admitted to
hospital and treated by a doctor with no experience of IPF: “I now have a heart problem as well as my
lungs. I got very upset about all this because nobody seemed to understand the conditions that I have. I
was in [hospital] for my heart, therefore nothing else mattered.” The patients also perceived inadequate
communication when asked to explain their condition time and time again to healthcare professionals.
They felt that maintaining and consulting concise, comprehensive patient medical records should reduce
this need.
The patients wanted specialist physicians always to communicate their diagnosis to their local doctor with
details about their treatment. The patients want to continue seeing their local doctor for IPF symptoms
and non-IPF health concerns but reported feeling vulnerable and lacking confidence in healthcare
professionals who were perceived to have little understanding of IPF: “I don’t think there is any point in
ringing my surgery now. My new doctor is OK but I don’t think she knows about my lungs.” The patients
felt that local and other primary care doctors would benefit from guidance from specialists.
Referral to rehabilitation and support services
Participants of the focus groups wanted referrals for early rehabilitation and quality of life services to be
available when they begin to lose physical independence or experience psychological challenges (such as at
diagnosis or the advanced planning stage). Nutrition and smoking cessation services could also be valuable
for some patients. They felt it was the physician’s responsibility to be aware of local services, and
communicate the importance of maintaining activity tolerance and support for psychological wellbeing: “I
think the best advice I was given was by an ILD consultant and nurse. ‘Do as much as you can.’”;
“Patients should be encouraged to stay as active as they can and as motivated as possible.” One patient
described how following her diagnosis and lack of information about staying active, her confidence was
severely affected, resulting in her becoming housebound. The physician should also stress the relationship
between physical activity and respiratory function for people being considered for lung transplantation,
and to people for whom pulmonary rehabilitation referral is not suitable, they should explain the reasons.
Social contact during rehabilitation was as important for most people as the physical activity component.
The psychological impact of IPF was stressed throughout. Anxiety and depression are common, with
anxiety most acute at the stages of diagnosis and disease progression. The patients who had received
counselling found that any scepticism about seeing a psychologist quickly disappeared after the first
contact. All patients agreed that emotional health should be a priority as well as physical health, and that
referral to a specialist psychologist with some knowledge of IPF can be exceptionally useful to help
patients get through the times when they feel down.
Patient−patient
Support groups and patient organisations
The focus group members were all involved with local support groups (Bristol support group) or national
patient organisations (ILFA, AMA Fuori dal buio and BVL), and were very positive about their role in
providing information and support to patients, carers and families. They noted initial anxieties around
meeting other patients and the encouragement provided by partners before they realised the value of
getting involved: “I didn’t feel I wanted to go because I thought it would be all older people, but when I
went I listened to all the speakers, everything was really helpful for me. I am really thankful. I said I am
going back again; it is a lot of help.”
The peer interaction at support groups provided positive benefits and learning opportunities for adapting
to life with IPF: “Patients will regularly talk to one another about their medication and give each other
tips.” Being able to talk face to face with other IPF patients helped them maintain a positive approach and
speaking with people who are at different stages of disease progression also had benefits: “People are
ultimately surprised by the opportunities still open to them and they realise, after talking to others in the
same position, that each case is different.”
Peer support was especially helpful for addressing anxieties around oxygen and lung transplantation. For
lung transplantation, is it useful to have the opportunity to meet others who have had a transplant both
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before and after the surgery to give hope and positive reinforcement that it is/was the right decision:
“Patients who are on the waiting list for a transplant gain courage from being around those who have
already had the operation. They can form a better picture as a result of contact with people who have had
a transplant.”
The patients felt that physicians and specialist centres should routinely inform patients about local support
groups and/or national organisations, clearly stating the information and support that they can offer and
the value that others have found in connecting with these groups. Information about patient organisations
should be displayed in ILD centres as well as printed information provided at diagnosis. This signposting
role is important because most of the focus group members were not aware of IPF before their diagnosis.
Carer and family support
The impact of IPF on the patient’s partner and family was raised by each focus group because the
“partners of people with lung fibrosis suffer with them”. Having a close relationship with someone with
IPF was described as a “heavy burden”, and therefore the carers’ and family members’ needs should not be
forgotten. Many patients described the importance of their partner attending their medical appointments
and being involved in the care pathway. Some patients reported “a total denial of the disease on the part of
the family”, with the result that the patient stopped communicating with the family about their condition
“so as not to create discomfort and anxiety”. Informing adult children of the diagnosis was also a major
challenge.
The carers in the focus groups agreed that patient organisations were an essential source of support and
information to them. This was considered especially important when the patient’s family had been less
involved in the patient’s care pathway, wanted more information about the diagnosis and prognosis, or
was struggling to accept the diagnosis. The carers described “how much they needed to encourage their
TABLE 3 A summary of actions proposed by the idiopathic pulmonary fibrosis (IPF) focus
groups that could improve communications and, hence, IPF care
Physician−patient communication
Specialist physicians should:
Always use plain language, and be honest and empathetic
Allow adequate time for questions at the end of the appointment
Ensure there is a follow-up appointment (or telephone/e-mail contact) 1–4 weeks after diagnosis,
when the patient has had time to digest their diagnosis and to formulate questions
Tailor information to the individual; the needs of each IPF patient will be different and will change
over time
Explain all treatment options to a patient, even those that are not an option for them and explain why
Encourage patients to keep a health diary and to report any changes in their health at each
appointment
Arrange a point of contact for the IPF patient, who can be contacted outside of scheduled
appointments
Recommend that the specialist centre provide a list of reliable information sources that the IPF
patient can go to for information
Provide clear guidance on medicines
Acknowledge and address any concerns with treatments that an IPF patient may be prescribed for
comorbidities
Raise the issue of end-of-life planning with their IPF patient when it is a medical imperative or the
patient requests information
Provide prompt access to a team trained in dealing with end-of-life issues
Explain the importance of remaining physically active to maintain health and for lung transplantation
to the patient
Physician−physician communication
IPF physicians should:
Consider providing IPF patients with printed information (factsheet) that clearly outlines what IPF is
and what treatment a patient is on, so that other HCPs can understand what the condition is
Ensure that the IPF patient’s local doctor is kept up to date with all changes in the patient’s care
Provide referrals for support services when they are needed (e.g. psychological support, smoking
cessation and nutritional advice)
Patient−patient communication
ILD specialist physicians and centres should routinely signpost patients and carers to local support
groups to facilitate peer support
HCP: healthcare professional; ILD: interstitial lung disease.
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loved ones to attend the support group and their initial reluctance” but “they all felt that having attended,
it was a very positive group and that in meeting others with similar problems and being able to help one
another, both those with IPF and their carers felt less isolated”.
A summary of actions proposed by the IPF focus groups that could improve communications and, hence,
IPF care are provided in table 3.
Discussion
This paper highlights a range of issues raised by patients and carers that are centred on communication
that when addressed, could improve the care and treatment of patients living with IPF.
Although not many studies have specifically focussed on communication issues in IPF, many of the points
that have been identified in this paper have been reported previously, including: adequate time for
consultation [2]; the importance of the IPF specialist in providing reliable and trustworthy sources of
further patient information, and there being a key point of contact [2, 6–9]; concern of patients who want
to understand how their stage of disease relates to its progression [8]; the desire for patients to have
someone to discuss issues around medicines [1, 10]; ensuring that local doctors are educated about IPF by
TABLE 4 An overview of the common points covered in the idiopathic pulmonary fibrosis (IPF) charters
Theme Europe Ireland UK Canada
Diagnosis Early and accurate
diagnosis
Early and accurate diagnosis
with multidisciplinary team
input
Timely and accurate diagnosis
and care involving an
appropriately skilled, specialist
multidisciplinary team
Timely and accurate diagnosis
and care, involving a skilled
specialist and a
multidisciplinary care team
Care Equal access to care Access to appropriate
medicines and oxygen
therapy
Access to seamless,
well-integrated health and
social care services, including
ambulatory and domiciliary
oxygen services personalised
to the needs of IPF patients
Equal levels of care across
Canada based on the best
standard of care currently
available
Information Comprehensive and
high-quality
information about
the condition
Clear and concise
information about IPF in
plain language
High-quality information about
the condition, including full
details of all treatment,
clinical trials, transplant,
support and service provision
options available to them
High-quality and accurate
information about IPF,
including full details of all
treatments, clinical trials,
support, service provisions
and transplant options
available to them
Holistic A holistic approach to
standardise IPF
management
Seamless, well-integrated health
and social care services,
including timely access to
ambulatory and personalised
home oxygen services and
appropriate IPF medications
Support Access to social, practical
and emotional support
Access to dedicated peer
support networks, both for
patients and their carers, in
person or digitally
Dedicated in-person or remote
peer support networks for
patients and their caregivers
Palliative care Better access to
palliative care and
end-of-life care
Specialist palliative care and
end-of-life care; supported by
the Gold Standards Framework
where appropriate
Improved, more accessible,
compassionate palliative and
end-of-life care when
appropriate
Pulmonary
rehabilitation
and transplant
Early referral to the National
Lung Transplant Unit for
lung transplant
assessment, with a
minimal emphasis on age
Early referral to pulmonary
rehabilitation and exercise
programmes
Swift access to specialist care
and IPF-tailored pulmonary
rehabilitation programmes,
appropriate prioritisation on
transplant waiting lists, and
prompt social care
assessments and response for
patients with exacerbations and
rapid disease progression
Bold text highlights where the point specifically relates to communication.
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the specialist and kept up to date with disease progression [11]; and increasing communication support as
patients get less well [12, 13].
Other studies have identified the need for early discussions to improve the patient and carer experience of
palliative care [13, 14]. One study argued that as the goal of end-of-life planning is to optimise function,
aid decision-making and improve quality of life, it should be introduced as a component of condition
management [15]. A recent study looking into end-of-life care with IPF patients found that end-of-life
decisions were still made very late. They concluded that early integrated palliative care with advance care
planning could improve the end-of-life care of IPF patients [16]. Another study has shown that end-of-life
discussion and planning as part of a multidisciplinary team can facilitate patients dying in their preferred
location [17]. We acknowledge that it was difficult to discuss this issue if even one person in a group was
uncomfortable with the conversation. Therefore, we can suppose that the opinions of the group may have
varied.
Patients greatly value support services around their interaction with the general medical community. Other
papers have also supported the view from our focus groups that wellbeing issues are important [2] and the
key role that pulmonary rehabilitation can play, especially around transplantation [11, 18, 19].
The psychological impact of IPF has been explored in other studies [20, 21]. Severe psychological distress
is experienced at diagnosis, and when patients have to give up employment and hobbies, and sometimes
also social activities, and risk becoming isolated.
The role of peer support came out very strongly in this study; perhaps this is to be expected, as the
individuals who took part were already part of such a group and therefore may be expected to advocate for
it. However, the role of support groups has been discussed positively in other studies as well [22].
It is clear that carers must not be excluded from communication involving IPF patients. Some 41% of the
focus group participants were carers and so it is not surprising that the importance of carers was well
covered [2, 7, 23].
Many of the points on communication are common to other disorders, and have been highlighted in
lymphangioleiomyomatosis [24] and lung cancer [25].
A number of IPF organisations have produced charters, outlining what is needed to improve the care of
people living with IPF, including in Ireland [26], the UK [27], Canada [28] and one that has been
developed for Europe [29, 30].
An overview of the points in each charter are given in table 4 and the points related to communication are
highlighted in bold. These charters give a clear direction of where patients with IPF see the need for
improvement and change. This paper reflects those points, and adds some more detail and context, and
practical suggestions to make that happen.
Clearly, this paper reflects discussions held with a limited number of IPF patients from selected countries
in Europe, which limits transfer of the outcomes to other geographical areas (e.g. Asia and Africa) where
the needs may be different. Efforts were made to ensure that the opinions reported here are reflective of
those individuals who took part in the groups, including providing systematic outlines for conducting the
focus groups and guidance on report writing. Several topics were not highlighted or discussed by the focus
groups (e.g. the role of healthcare systems) and this is a limiting factor to the way patient input was
gathered.
Conclusions
Patients with IPF and their carers reported communication challenges in interactions with healthcare
professionals, between healthcare professionals and from patient to patient, during four focus groups held
in different countries in Europe.
Poor communication can lead to low confidence and anxiety about the quality of care and services IPF
patients receive, and concerns about the management of medication and comorbidities. Effective
communication is also vital to support psychological wellbeing.
Patients and carers look to their specialist ILD physician and centres to provide them with accessible
information, medical support and signposting to groups and services to support and involve them
throughout their care pathway.
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